Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
Open Access
- 27 November 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 7 (1), 44-51
- https://doi.org/10.1016/s2213-8587(18)30306-1
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (C18243/A5802)
This publication has 30 references indexed in Scilit:
- Scoring system for predicting recurrences in patients with papillary thyroid microcarcinomaActa Endocrinologica, 2012
- Thyroid cancer: successful remnant ablation-what is success?Nature Reviews Endocrinology, 2012
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid CancerThe New England Journal of Medicine, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerThe New England Journal of Medicine, 2012
- Impact on Overall Survival of Radioactive Iodine in Low-Risk Differentiated Thyroid Cancer PatientsJournal of Clinical Endocrinology & Metabolism, 2012
- The Effectiveness of Radioactive Iodine for Treatment of Low-Risk Thyroid Cancer: A Systematic Analysis of the Peer-Reviewed Literature from 1966 to April 2008Thyroid®, 2010
- Recurrence After Treatment of Micropapillary Thyroid CancerThyroid®, 2009
- Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year periodSurgery, 2008
- Long‐term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatmentClinical Endocrinology, 2008
- An Updated Systematic Review and Commentary Examining the Effectiveness of Radioactive Iodine Remnant Ablation in Well-Differentiated Thyroid CancerEndocrinology and Metabolism Clinics of North America, 2008